Aviso Financial Inc. Has $1.24 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Aviso Financial Inc. lifted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 71.6% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,165 shares of the pharmaceutical company’s stock after buying an additional 1,321 shares during the period. Aviso Financial Inc.’s holdings in Vertex Pharmaceuticals were worth $1,240,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of VRTX. Chesapeake Asset Management LLC raised its stake in Vertex Pharmaceuticals by 110.0% during the third quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after acquiring an additional 33 shares in the last quarter. Access Investment Management LLC acquired a new position in Vertex Pharmaceuticals during the 2nd quarter worth approximately $27,000. Colonial Trust Co SC lifted its stake in Vertex Pharmaceuticals by 118.8% in the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 38 shares during the last quarter. Legacy Investment Solutions LLC acquired a new stake in Vertex Pharmaceuticals in the second quarter valued at approximately $29,000. Finally, Total Investment Management Inc. bought a new stake in shares of Vertex Pharmaceuticals during the second quarter worth $33,000. 90.96% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. HC Wainwright set a $591.00 price target on Vertex Pharmaceuticals in a research note on Tuesday, February 17th. Wolfe Research raised Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 target price for the company in a report on Tuesday, January 6th. Barclays lifted their price target on Vertex Pharmaceuticals from $606.00 to $607.00 and gave the company an “overweight” rating in a research note on Tuesday, February 17th. Royal Bank Of Canada lowered their price objective on Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating for the company in a research note on Friday, February 13th. Finally, Wells Fargo & Company raised their price objective on shares of Vertex Pharmaceuticals from $460.00 to $515.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Twenty-two research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $542.00.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Clinical safety expansion — Vertex announced a new study to evaluate VX‑548 (an investigational pain drug) in breastfeeding women, broadening the drug’s safety profile and de‑risking development pathways if results are supportive. Vertex Expands VX‑548 Safety Profile With New Breastfeeding Study
• Positive Sentiment: Leadership/PR tailwind — TIME profiled CEO Reshma Kewalramani, reinforcing investor confidence in management’s execution and Vertex’s strategy to expand beyond cystic fibrosis. Physician‑Scientist Reshma Kewalramani Runs One of Biotech’s Biggest Companies
• Positive Sentiment: Analyst support — recent upgrades and raised price targets (several firms highlighted in coverage) help underpin the stock and attract buy‑side interest. MarketBeat VRTX analyst coverage
• Neutral Sentiment: Quarterly fundamentals — Q4 revenue rose ~9.5% y/y and margins remain strong, though EPS missed by $0.02 (reported $5.03 vs. $5.05 consensus); this is a small miss that keeps the longer‑term thesis intact but mutes near‑term upside. Vertex recent earnings summary
• Neutral Sentiment: Momentum/coverage — pieces asking whether VRTX is outperforming major indices may draw momentum flows but do not represent new fundamental catalysts. Is Vertex Stock Outperforming the Dow?
• Negative Sentiment: Clustered insider selling — multiple senior executives disclosed sales between Feb. 19–25, including a large sale by EVP Amit Sachdev (~58,613 shares, ~ $27.5M) and several other EVPs reducing positions. Such concentrated insider sales can create near‑term negative sentiment even if driven by diversification or tax planning. Representative SEC filing: SEC Form 4 – Amit Sachdev
• Negative Sentiment: Additional officer sale — CAO Kristen Ambrose sold 223 shares (minor relative to the EVP sales) but is part of the broader disclosure set that traders are reacting to. Vertex insider sales roundup

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $496.83 on Monday. The company’s 50 day moving average price is $466.55 and its 200-day moving average price is $432.55. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.68. The company has a market capitalization of $126.21 billion, a P/E ratio of 32.41 and a beta of 0.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing the consensus estimate of $5.05 by ($0.02). The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the company earned $3.98 earnings per share. Analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Insider Activity at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 260 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total transaction of $126,451.00. Following the completion of the sale, the executive vice president owned 46,763 shares of the company’s stock, valued at $22,743,185.05. This trade represents a 0.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Mark E. Bunnage sold 620 shares of the business’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total transaction of $301,537.00. Following the transaction, the executive vice president owned 7,284 shares in the company, valued at $3,542,573.40. The trade was a 7.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 168,937 shares of company stock worth $77,879,922 over the last quarter. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.